Silo Pharma Announces Promising Preclinical Results for SP-26, a Novel Ketamine Implant for Fibromyalgia

Silo Pharma (NASDAQ: SILO) has reported encouraging preclinical outcomes for SP-26, its innovative extended-release ketamine implant designed to treat fibromyalgia. The study, conducted in minipigs, successfully met all its endpoints, including safety, tolerability, and pharmacokinetics, with no adverse events related to the implant and sustained ketamine release observed for up to 22 days. According to CEO Eric Weisblum, these findings bolster the case for SP-26's progression as a next-generation, abuse-deterrent pain therapy. Unlike intravenous ketamine, SP-26 is administered subcutaneously, circumventing dissociative effects and presenting a potentially safer alternative to opioids. This development could pave the way for SP-26 to become the first at-home injectable ketamine-based therapeutic.

SP-26 represents a significant advancement in the treatment of chronic pain conditions, offering hope to patients seeking alternatives to traditional pain management strategies. The success of this preclinical study underscores the potential of psychedelic-based treatments in addressing underserved medical conditions. Silo Pharma's focus on developing novel formulations and drug-delivery systems, as evidenced by SP-26, highlights the company's commitment to innovation in the biopharmaceutical sector. For more details on the study, visit https://ibn.fm/APuat.

The implications of SP-26's development extend beyond fibromyalgia, suggesting a broader application for ketamine-based therapies in chronic pain management. As the medical community continues to explore the therapeutic potential of psychedelics, Silo Pharma's work with SP-26 could signal a shift towards more accessible and safer treatment options for patients worldwide. The company's collaboration with universities and independent laboratories further emphasizes the importance of interdisciplinary research in advancing psychedelic medicine.